Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
July 11, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today...
Monopar to Participate in the Radiopharma Forum by the Lake 2023
June 21, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
May 11, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2)MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE...
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
February 27, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced...
Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99
December 21, 2022 10:26 ET
|
Curium
PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20...
Nuclear Medicine Outlook: Proven Molybdenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
November 08, 2022 13:05 ET
|
Curium
Measures in place minimize impact of near-term molybdenum-99 shortageMore than ten years of Mo-99 supply chain resilienceCooperation, investment, and facility upgrades for the benefit of patients ...
Global Prostate Cancer Nuclear Medicine Diagnostics Market Report 2022-2028 - Increasing Research Activities for Development of Innovative Imaging Agents
August 31, 2022 06:28 ET
|
Research and Markets
Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report...
Radiopharmaceuticals Global Market Report 2022: Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
August 23, 2022 06:13 ET
|
Research and Markets
Dublin, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
June 27, 2022 01:00 ET
|
Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
May 12, 2022 01:05 ET
|
Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...